These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 445331

  • 1. Adjuvant immunotherapy of malignant melanoma.
    Aranha GV, McKhann CF, Grage TB, Gunnarsson A, Simmons RL.
    Cancer; 1979 Apr; 43(4):1297-303. PubMed ID: 445331
    [Abstract] [Full Text] [Related]

  • 2. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
    Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, Bufalino R, Cascinelli N, Cocconi G, Durand J, De Marsillac J, Ikonopisov RL, Kiss B, Lejeune F, MacKie R, Madej G, Mulder H, Mechl Z, Milton GW, Morabito A, Peter H, Priario J, Paul E, Rumke P, Sertoli R, Tomin R.
    N Engl J Med; 1982 Oct 07; 307(15):913-6. PubMed ID: 7050717
    [Abstract] [Full Text] [Related]

  • 3. Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer.
    Gray BN, Walker C, Andrewartha L, Freeman S, Bennett RC.
    J Surg Oncol; 1989 Jan 07; 40(1):34-7. PubMed ID: 2642566
    [Abstract] [Full Text] [Related]

  • 4. Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.
    Veronesi U, Beretta G.
    Recent Results Cancer Res; 1978 Jan 07; 68():375-9. PubMed ID: 752873
    [No Abstract] [Full Text] [Related]

  • 5. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
    Sterchi JM, Wells HB, Case LD, Spurr CL, White DR, Richards F, Muss HB, Jackson DV, Stuart JJ, Cooper MR.
    Cancer; 1985 Feb 15; 55(4):707-12. PubMed ID: 3967167
    [Abstract] [Full Text] [Related]

  • 6. [Current results with surgery and adjuvant chemotherapy in malignant melanoma].
    Mechl Z, Kopecný J.
    Arch Geschwulstforsch; 1986 Feb 15; 56(5):367-71. PubMed ID: 2429631
    [Abstract] [Full Text] [Related]

  • 7. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V, Knopf B.
    Arch Geschwulstforsch; 1981 Feb 15; 51(6):493-6. PubMed ID: 7332442
    [Abstract] [Full Text] [Related]

  • 8. Immunotherapy and chemotherapy in children with neuroblastoma.
    Nesbit ME, Kersey J, Finklestein J, Weiner J, Simmons R.
    J Natl Cancer Inst; 1976 Sep 15; 57(3):717-20. PubMed ID: 978774
    [Abstract] [Full Text] [Related]

  • 9. [Experiments on the treatment of Yoshida tumor with neuroaminidase of Vibrio cholerae].
    Sánchez Cousteau JA, Justo Alpañes E, Ledro Molina D, Ferreiro Madueño M, Gomez Parra M, Ramírez Martínez R, Valle Bernal MJ, Astolfi Pérez de Guzmán J, Garrido Peralta M.
    Rev Clin Esp; 1979 Sep 15; 154(5):183-6. PubMed ID: 523718
    [No Abstract] [Full Text] [Related]

  • 10. Adjuvant therapy in malignant melanoma: a trial of immunotherapy. chemotherapy, and combined treatment.
    Kaufman SD, Cosimi AB, Wood WC, Carey RW.
    Recent Results Cancer Res; 1978 Sep 15; 68():380-6. PubMed ID: 752874
    [No Abstract] [Full Text] [Related]

  • 11. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
    Agarwala SS, Neuberg D, Park Y, Kirkwood JM.
    Cancer; 2004 Apr 15; 100(8):1692-8. PubMed ID: 15073858
    [Abstract] [Full Text] [Related]

  • 12. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
    Hedley DW, McElwain TJ, Currie GA.
    Br J Cancer; 1978 Apr 15; 37(4):491-6. PubMed ID: 646922
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
    Peter HH, Deutschmann KE, Deinhardt J, Deicher H.
    Recent Results Cancer Res; 1978 Apr 15; 68():367-74. PubMed ID: 752872
    [No Abstract] [Full Text] [Related]

  • 15. Immunotherapy of malignant melanoma.
    Thiers BH.
    J Am Acad Dermatol; 1982 Apr 15; 6(4 Pt 1):559-62. PubMed ID: 6176602
    [No Abstract] [Full Text] [Related]

  • 16. Clinical results with immunochemotherapy in 40 cases of advanced tumour.
    Narcisi M.
    Panminerva Med; 1975 Apr 15; 17(5-6):208-10. PubMed ID: 1161322
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK, Ibrahim EM, Evers JA, Thomas JW, Murray RN, Spinelli JJ.
    Can Med Assoc J; 1983 Jun 01; 128(11):1291-5. PubMed ID: 6342739
    [Abstract] [Full Text] [Related]

  • 19. Systemic therapy of malignant melanoma.
    Seeger J, Richman SP, Allegra JC.
    Med Clin North Am; 1986 Jan 01; 70(1):89-94. PubMed ID: 3510351
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.